{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:44Z","timestamp":1791921524165,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 AI148365-01A1"],"award-info":[{"award-number":["1R01 AI148365-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012483","name":"University of Georgia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fungal infections are responsible for &amp;gt;1.5 million deaths globally per year, primarily in those with compromised immune function. This is concerning as the number of immunocompromised patients, especially in those without human immunodeficiency virus (HIV), has risen in the past decade. The purpose of this analysis was to provide the current prevalence and impact of fungal disease in the United States.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed hospital discharge data from the most recent (2018) Healthcare Cost and Utilization Project National Inpatient Sample, and outpatient visit data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Costs are presented in 2018 United States (US) dollars.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the 35.5 million inpatient visits documented in 2018 in the US, approximately 666\u00a0235 fungal infections were diagnosed, with an estimated attributable cost of $6.7 billion. Aspergillus, Pneumocystis, and Candida infections accounted for 76.3% of fungal infections diagnosed, and 81.1% of associated costs. Most fungal disease occurred in patients with elevated risk of infection. The visit costs, lengths of stay, and risks of mortality in this population were more than twice that of those without fungal diagnoses. A further 6.6 million fungal infections were diagnosed during outpatient visits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fungal disease is a serious clinical concern with substantial healthcare costs and significant increases in morbidity and mortality, particularly among predisposed patients. Increased surveillance, standardized treatment guidelines, and improvement in diagnostics and therapeutics are needed to support the rising numbers of at-risk patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofab593","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T19:06:19Z","timestamp":1642014379000},"source":"Crossref","is-referenced-by-count":224,"title":["Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-3475","authenticated-orcid":false,"given":"Emily","family":"Rayens","sequence":"first","affiliation":[{"name":"Center for Vaccines and Immunology, Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A","family":"Norris","sequence":"additional","affiliation":[{"name":"Center for Vaccines and Immunology, Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"2022011219041249200_CIT0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision.","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi"},{"key":"2022011219041249200_CIT0002","doi-asserted-by":"crossref","first-page":"e0007964","DOI":"10.1371\/journal.pntd.0007964","article-title":"Fungal diseases as neglected pathogens: a wake-up call to public health officials.","volume":"14","author":"Rodrigues","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2022011219041249200_CIT0003","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.chest.2019.06.032","article-title":"Advances in the diagnosis and management of invasive fungal disease.","volume":"156","author":"Formanek","year":"2019","journal-title":"Chest"},{"key":"2022011219041249200_CIT0004","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJM198112103052402","article-title":"An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.","volume":"305","author":"Masur","year":"1981","journal-title":"N Engl J Med"},{"key":"2022011219041249200_CIT0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/322606","article-title":"Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.","volume":"33","author":"McNeil","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2022011219041249200_CIT0006","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab336","article-title":"Mortality trends in risk conditions and invasive mycotic disease in the United States, 1999-2018 [manuscript published online ahead of print 20 April 2021].","author":"Rayens","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022011219041249200_CIT0007","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022011219041249200_CIT0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijantimicag.2011.11.017","article-title":"Invasive fungal infections in patients with cancer in the intensive care unit.","volume":"39","author":"Sipsas","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2022011219041249200_CIT0009","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar4480","article-title":"Rheumatoid arthritis patients exhibit impaired Candida albicans\u2013specific Th17 responses.","volume":"16","author":"Bishu","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022011219041249200_CIT0010","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3899\/jrheum.111498","article-title":"Invasive fungal infections in patients with systemic lupus erythematosus.","volume":"39","author":"Martinez-Martinez","year":"2012","journal-title":"J Rheumatol"},{"key":"2022011219041249200_CIT0011","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3899\/jrheum.150142","article-title":"A multicenter study of invasive fungal infections in patients with childhood-onset systemic lupus erythematosus.","volume":"42","author":"Silva","year":"2015","journal-title":"J Rheumatol"},{"key":"2022011219041249200_CIT0012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/09031936.06.00074705","article-title":"The link between fungi and severe asthma: a summary of the evidence.","volume":"27","author":"Denning","year":"2006","journal-title":"Eur Respir J"},{"key":"2022011219041249200_CIT0013","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cmi.2016.05.016","article-title":"New clinical phenotypes of fungal infections in special hosts.","volume":"22","author":"Pilmis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2022011219041249200_CIT0014","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1086\/591701","article-title":"Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease.","volume":"47","author":"Morris","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022011219041249200_CIT0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/jcm8010076","article-title":"Candida sp. infections in patients with diabetes mellitus.","volume":"8","author":"Rodrigues","year":"2019","journal-title":"J Clin Med"},{"key":"2022011219041249200_CIT0016","first-page":"296","article-title":"Weight loss and diabetes are new risk factors for the development of invasive aspergillosis infection in non-immunocompromized humans.","volume":"14","author":"Ghanaat","year":"2017","journal-title":"Clin Pract"},{"key":"2022011219041249200_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2016.05.001","article-title":"Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis.","volume":"73","author":"Green","year":"2016","journal-title":"J Infect"},{"key":"2022011219041249200_CIT0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.09-1103","article-title":"The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis.","volume":"137","author":"Amin","year":"2010","journal-title":"Chest"},{"key":"2022011219041249200_CIT0019","doi-asserted-by":"crossref","first-page":"e1008742","DOI":"10.1371\/journal.ppat.1008742","article-title":"Post-tuberculosis chronic pulmonary aspergillosis: an emerging public health concern.","volume":"16","author":"Bongomin","year":"2020","journal-title":"PLoS Pathog"},{"key":"2022011219041249200_CIT0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0000000000000504","article-title":"Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment.","volume":"31","author":"Vanderbeke","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2022011219041249200_CIT0021","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/CCM.0000000000004861","article-title":"The extend of aspergillosis in critically ill patients with severe influenza pneumonia: a multicenter cohort study.","volume":"49","author":"Coste","year":"2021","journal-title":"Crit Care Med"},{"key":"2022011219041249200_CIT0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3201\/eid2701.202896","article-title":"Aspergillosis complicating severe coronavirus disease.","volume":"27","author":"Marr","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2022011219041249200_CIT0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/myc.13254","article-title":"COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series.","volume":"64","author":"Meijer","year":"2021","journal-title":"Mycoses"},{"key":"2022011219041249200_CIT0024","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/myc.13338","article-title":"COVID-19-associated mucormycosis: an updated systematic review of literature.","volume":"64","author":"Pal","year":"2021","journal-title":"Mycoses"},{"key":"2022011219041249200_CIT0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.idc.2006.07.002","article-title":"Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis.","volume":"20","author":"Kauffman","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"2022011219041249200_CIT0026","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of direct healthcare costs of fungal diseases in the United States.","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022011219041249200_CIT0027","volume-title":"Healthcare Cost and Utilization Project (HCUP)","author":"HCUP National Inpatient Sample, Agency for Healthcare Research and Quality.","year":"2012"},{"key":"2022011219041249200_CIT0028","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.","volume":"95","author":"Kim","year":"2020","journal-title":"Am J Hematol"},{"key":"2022011219041249200_CIT0029","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5435\/JAAOS-22-06-390","article-title":"Fungal osteomyelitis and septic arthritis.","volume":"22","author":"Bariteau","year":"2014","journal-title":"J Am Acad Orthop Surg"},{"key":"2022011219041249200_CIT0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10916-018-0936-3","article-title":"Validation of the All Patient Refined Diagnosis Related Group (APR-DRG) risk of mortality and severity of illness modifiers as a measure of perioperative risk.","volume":"42","author":"McCormick","year":"2018","journal-title":"J Med Syst"},{"key":"2022011219041249200_CIT0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"2022011219041249200_CIT0032","first-page":"1","article-title":"Ambulatory surgery data from hospitals and ambulatory surgery centers: United States, 2010.","volume":"102","author":"Hall","year":"2017","journal-title":"Natl Health Stat Report"},{"key":"2022011219041249200_CIT0033","author":"Centers for Medicare and Medicaid Services."},{"key":"2022011219041249200_CIT0034","doi-asserted-by":"crossref","first-page":"e2016040","DOI":"10.4084\/mjhid.2016.040","article-title":"Antifungal prophylaxis in immunocompromised patients.","volume":"8","author":"Vazquez","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2022011219041249200_CIT0035","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/JCM.01283-12","article-title":"Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.","volume":"50","author":"Lockhart","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2022011219041249200_CIT0036","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hoc.2010.11.013","article-title":"Fungal infections in transplant and oncology patients.","volume":"25","author":"Person","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022011219041249200_CIT0037","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/2040620711410098","article-title":"Invasive fungal infections in acute leukemia.","volume":"2","author":"Bhatt","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"2022011219041249200_CIT0038","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12703\/P6-81","article-title":"Epidemiology of invasive fungal diseases on the basis of autopsy reports.","volume":"6","author":"Dignani","year":"2014","journal-title":"F1000Prime Rep"},{"key":"2022011219041249200_CIT0039","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/MLR.0000000000001010","article-title":"ICD-10 coding will challenge researchers: caution and collaboration may reduce measurement error and improve comparability over time.","volume":"57","author":"Mainor","year":"2019","journal-title":"Med Care"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/1\/ofab593\/42123381\/ofab593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/1\/ofab593\/42123381\/ofab593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T19:06:55Z","timestamp":1642014415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab593\/6502318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab593","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"ofab593"}}